Recent testing and evaluation have shown that Utah company Co-Diagnostics’ COVID-19 test is doing just what it was designed to do, according to a release from the company. The company has published data that shows the test has 100 percent sensitivity and 100 percent specificity, the two metrics used to define accuracy in molecular diagnostics testing.
The data being released comes from independent evaluations of the performance of the Co-Diagnostics’ COVID-19 test in the field. These evaluations include the India National Institute of Pathology, the Mexican Department of Epidemiology and others in the U.S. and abroad. Each study concluded 100 percent concordance for both specificity and sensitivity.
In remarking on the test’s favorable results in the evaluations, Brent Satterfield, the company’s chief science officer and co-founder, said, “In diagnostics, the limit of detection or LOD is a single metric that helps inform the key metrics of sensitivity and specificity but is not relevant as a stand-alone data point. Other metrics that are important are availability, ease of use and throughput. In countries where we have been evaluated against other tests, we have consistently and repeatedly achieved 100 percent clinical sensitivity and specificity and you can’t do better than that.”
In the United States, Co-Diagnostics has been a supplier for tests around the country including in its home state of Utah, as a supplier for TestUtah, a public-private partnership organized by Silicon Slopes and the state of Utah to “Crush the Curve” in the state. The goals of this initiative include dramatically increasing health assessments, testing capacity and accessibility.